Review of current issues in pharmaceutical excipients

Pharmaceutical Technology

Volumn 31, Issue 5, 2007, Pages 56-66

  Chang, Dorothy ^a   Chang, Rong Kun ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b Supernus Pharmaceuticals Inc   (United States)

Author keywords

Excipients; Formulation; USP

Indexed keywords

EXCIPIENTS; FORMULATION DESIGN; THERAPEUTIC BENEFITS;

DRUG PRODUCTS; INDUSTRIAL ECONOMICS; PRODUCT DEVELOPMENT;

PRODUCT DESIGN;

AEROSIL; AMYLIN; EXCIPIENT; INSULIN DETEMIR; PEPTIDE; UNCLASSIFIED DRUG; XYLITAB;

DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SYNTHESIS; EXCIPIENT COMPATIBILITY; REVIEW;

EID: 34248330934     PISSN: 15432521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. M. Ash and I. Ash, Handbook of Pharmaceutical Additives (Gower Publishing Limited, Hampshire, England, 1995).
2. Handbook of Pharmaceutical Excipients, R. Rowe, P.J. Sheskey, and P. J. Weller, Eds. (Pharmaceutical Press and American Pharmaceutical Association, Chicago, IL, 2003).
3. International Pharmaceutical Excipients Council-Americas, "What are Pharmaceutical Excipients?" www.ipecamericas.org/public/faqs. html#question1.
4. Center for Drug Evaluation and Research (CDER), "Inactive Ingredient Search for Approved Drug Products," www.accessdata.fda.gov/ scripts/cder/iig/index.cfm.
5. CDER, Quality Systems Approach to Pharmaceutical Good Manufacturing Practices, Draft Guidance (Rockville, MD, 2004).
6. S.U. Ahmed, V.Naini, and S.R. Vaithiyalingam, "Physicochemical Characteristics of Drugs and Excipients: An Overview," Amer. Pharm. Rev. 9 (3), 47-52 (2006).
7. J.R. Johanson, "Defining the Physical Functionality of Excipients, Bulk Drugs and Formulations," Innovations in Pharmaceutical Technology 1 (2), 136-146 (1999).
8. D. Bugay and W.P. Findlay, Pharmaceutical Excipients: Characterization by IR, Raman, and NMR Spectroscopy (Marcel Dekker, Inc., New York, NY, 1999).
9. B.D. Rege et al., "Effect of Common Excipients on Caco-2 Transport of Low-Permeability Drugs," J. Pharm. Sci. 90 (11), 1776-1786 (2001).
10. P.D. Ward, T.K. Tippin, and D.R. Thakker, "Enhancing Paracellular Permeability by Modulating Epithelial Tight Junctions," PSST 3, (10), 348-358 (2000).
11. R. Chang and P. Bhatt, "Recent Trends in Oral Drug Delivery," AAPS Newsmagazine, 18-21 (March 2005).
12. "Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems," A. Katdare and M. Chaubal, Eds. (Informa Healthcare USA, New York, NY, July 2006).
13. J.M. Smith and T.R. Dodd, "Adverse Reactions to Pharmaceutical Excipients," Adv. Drug React. Ac. Pois. Rev. 1, 93-142 (1982).
14. Excipient Toxicity and Safety, W. Kotkoski, M. Weiner, L. Kotkoskie, Eds. (Marcel Dekker, New York, NY, 1999).
15. K. Jackson, D. Young, and S. Pant, "Drug-Excipient Interactions and Their Affect on Absorption," PSTT 3 (10), 338-345 (2000).
16. P.J. Weller, "Ceratonia," in Handbook of Pharmaceutical Excipients, R.C. Rowe, P.J. Sheskey, and P.J. Weller, Eds. (Pharmaceutical Press and American Pharmaceutical Association, Chicago, IL, 2003), pp. 123-124.
17. B. Wittgren, M. Stefansson, and B. Porsch, "Interactions between Sodium Dodecyl Sulphate and Non-Ionic Cellulose Derivatives Studies by Size Exclusion Chromatography with Online Multiangle Light Scattering and Refractometric Detection," J. Chromatogr. A. 1082 (2), 166-175 (2005).
18. J.A. Menendez et al., " A Genomic Explanation Connecting Mediterranean Diet, Olive Oil, and Cancer: Oleic Acid, the Main Monounsaturated Fatty Acid of Olive Oil, Induces Formation of Inhibitory PEA3 Transcription Factor-PEA3 DNA Binding Site Complexes at Her-2/neu (erbB-2) Oncogene Promoter in Breast, Ovarian, and Stomach Cancer Cells," Eur. J. Cancer (Jan. 4, 2006).
19. J.A. Menendez et al., "Effect of Gamma-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene," J. Natl. Cancer Inst. 97 (21), 1611-1615 (2005).
20. J.A. Menendez, R. Lupu, and R. Colomer, "Targeting Fatty Acid Synthase: Potential for Therapeutic Intervention in Her-2/neu-Over-Expressing Breast Cancer," Drug News Perspect. Jul.-Aug, 18 (6), 375-85 (2005)
21. M. Uhari, T. Kontiokari, and M. Niemela, "A Novel Use of Xylitol Sugar in Preventing Acute Otitis Media," Pediatrics 102 (4), 879-884 (1998).
22. "FDA Issues Glucose Meter Safety Warning," DOC News 3 (1), 7, docnews.diabetesjournals.org/cgi/content/full/3/1/7, accessed April 1, 2007.
23. A.M. Cattelan et al., "Use of Polylactic Acid Implants to Correct Facial Lipoatrophy in Human Immunodeficiency Virus 1-Positive Individuals Receiving Combination Antiretroviral Therapy," Arch Dermatol. 142 (3), 362-364 (2006).
24. T. Gyotoku, L. Aurelian, and A.R. Neurath, "Cellulose Acetate Phthalate (CAP): An 'Inactive' Pharmaceutical Excipient with Antiviral Activity in the Mouse Model of Genital Herpesvirus Infection," Antiviral Chem. Chemotherapy 10, 327-332 (1999).
25. www.aromatherapy.com/essentialoils.html.
26. www.ars.usda.gov/is/AR/archive/apr04/cinnam0404.html.
27. J. Morton, "Taking the Color of Medications Seriously," www.colormatters.com/body_pills.html, accessed April 1, 2007.
28. Capsugel List of Colorants for Oral Drugs, 11th ed. (Pfizer Inc. Capsugel Division, 2002).